Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells

作者：Kim Sangmin; Lee Jeongmin; Oh Soo Jin; Nam Seok Jin^*; Lee Jeong Eon

来源：Oncology Reports, 2015, 34(3): 1613-1619.

DOI：10.3892/or.2015.4116

• ER-alpha
• EGFR inhibitor
• mesenchymal marker protein
• tamoxifen resistance

Although tamoxifen is the most common and effective therapy for treatment of estrogen receptor-alpha (ER-alpha) breast cancer patients, resistance of endocrine therapy occurs, either de novo or acquired during therapy. Here, we investigated the clinical value of epidermal growth factor receptor (EGFR) in tamoxifen-resistant (TamR) patients and the differential effect of EGFR inhibitors, neratinib and gefitinib, on TamR breast cancer cell model. The morphology of TamR MCF7 cells showed mesenchymal phenotypes and did not induce cell death by tamoxifen treatment compared with tamoxifen-sensitive (TamS) MCF7 cells. In addition, mesenchymal marker proteins, including N-cadherin (N-cad), fibronectin (FN), and Slug, significantly increased in TamR cells. In contrast, ER-alpha and E-cadherin (E-cad) were greatly decreased. We also found that the levels of EGFR and HER2 expression were increased in TamR cells. Furthermore, we observed that EGFR expression was directly involved with poor prognosis of tamoxifen-treated breast cancer patients using the GSE1378 date set. Thus, we treated TamR and TamS cells with EGFR inhibitors, neratinib and gefitinib, respectively. Interestingly, neratinib induced apoptotic cell death of TamR but not gefitinib. Cleaved PARP-1 expression was also increased by neratinib treatment in TamR cells. Therefore, we suggest that neratinib may be a potential therapeutic drug for treating TamR breast cancer.

• 出版日期2015-9